3Di Napoli P, Taccardi A A, Barsotti A. Long-term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischemic dilated cardiomyopathy[J]. Heart, 2005,91 (2) : 161-165.
4Allibardi S, Chierchia S L, Margonato V, et al. Effects of trimetazidine on metabolic and functional recovery of postischemic rat hearts[J]. Cardiovasc Drugs Ther, 1998,12(6): 543- 549.
5Killalea S M, Krum H. Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease [J]. Am J Cardiovasc Drugs, 2001,1 (3) : 193-204.
6Kantor P F, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long -chain 3-ketoacyl coenzyme A thiolase[J]. Circ Res,2000,86(5) :580-588.
7陈新谦.新药治疗研究指导原则[M].北京:人民卫生出版社,1994.217-218.
8Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol, 1997, 80(11A) : 15L-25L
9Braunwald E,Bristow MR Congestive heart failure: fifty years of progress. Circulation, 2000, 102(20 Suppl 4) : Ⅳ14-23.
10Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) : developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation, 2005, 112 (12) :e154-235.
